Insmed to present new Phase 3b ENCORE data on ARIKAYCE resistance in newly diagnosed MAC lung disease at IDWeek 2026

Insmed flagged new clinical data across TPIP, BRINSUPRI, ARIKAYCE for presentation at CHEST 2026 and IDWeek 2026. Results will be presented in the future, with late-breaking TPIP updates aimed at supporting longer-term use in PAH, PH-ILD. A new Phase 3 ASPEN post hoc analysis will link patient-reported sputum color to inflammatory activity, exacerbation risk in bronchiectasis. IDWeek presentations will report ENCORE findings on antibiotic resistance development in newly diagnosed MAC lung disease, supported by real-world outcomes analysis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via (Ref. ID: 202610140700PR_NEWS_USPR_____NY71485) on October 14, 2026, and is solely responsible for the information contained therein. (C)